ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,937 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselTOLREMO therapeutics AG
TOLREMO therapeutics AG Logo
Verified· 4 sourcesTrust Score
Summary

About the company

The core activity of TOLREMO therapeutics AG is the development of therapeutic solutions to combat cancer, particularly to overcome cancer resistance to targeted therapies. The company focuses on the development of active ingredients that are intended to inhibit the early transcriptional reprogramming of cancer cells, the first line of defense against targeted therapies, in order to improve the efficacy of cancer treatments.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.0/5

TOLREMO therapeutics AG

✓ Offered3
Development of cancer therapies against non-genetic drug resistance
Development of small molecules and therapeutic approaches to block transcriptional reprogramming, preventing early and acquired cancer drug resistance.
Development of TT125-802
Development of the orally available, selective CBP/p300 bromodomain inhibitor TT125-802 as monotherapy and in combination with targeted therapies in solid tumors and haematological malignancies.
Clinical development of TT125-802
Phase I dose-escalation study of TT125-802 as monotherapy in patients with solid tumors, along with further clinical development with targeted therapies.
Trust & reputation

ranQ Trust Score of TOLREMO therapeutics AG: 4.0 out of 5.0

Trust Score4.0/ 5.0

High

x

Data basis 100% · As of October 2026

TOLREMO therapeutics AG scores 56.6 out of 100 points in the Reputation area of the ranQ Trust Score. This area carries 42% of the weighting.
x
CriterionValueWeight
  • Review quality: The average rating across all connected sources, smoothed against the industry mean. So 5.0 stars from three reviews do not outrank 4.7 from three hundred.70.824%
  • Review volume: The number of reviews across all sources. The scale is logarithmic: the first reviews count the most, and the maximum is reached at 50 reviews.27.910%
  • Review recency: The age of the most recent review. Two-year-old reviews deliberately sit in the middle, because that is normal for Swiss SMEs. Only after three years without a new voice does the value drop markedly.50.08%
TOLREMO therapeutics AG scores 82.0 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.83.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.70.07%
TOLREMO therapeutics AG scores 86.7 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).86.722%
TOLREMO therapeutics AG scores 61.5 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.82.94%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.40.04%
Qualifications+0.00

TOLREMO therapeutics AG reaches a ranQ Trust Score of 4.0 out of 5.0 — rated «High». The rating draws, among other things, on 5.0 out of 5 stars from 2 customer reviews. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Reviews

Aggregated rating

Aggregated rating
5
of 5

Aggregated from 2 reviews across all connected sources

Sources
GGoogle52
★TrustpilotSoon
PProvenExpertSoon

Further sources are added continuously and factored into the ranQ Rating.

Press

Media

July 8, 2022Media
Tolremo’s founder Stefanie Flückiger-Mangual is the Innovator of the Year
startupticker.ch
June 10, 2020Media
Additional capital for TOLREMO therapeutics
startupticker.ch
September 24, 2018Media
TOLREMO raises CHF9 million series A financing round
startupticker.ch
September 19, 2017Media
Biotech start-up TOLREMO closes CHF2,4 million financing round
startupticker.ch

Knowledge

No knowledge articles yet

Once TOLREMO therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

TOLREMO therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank TOLREMO therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of TOLREMO therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hochbergerstrasse 60C
4057 Basel

At a glance

Legal form
Corporation
UID
CHE-350.476.582
Founded
2017 · 9 years
Last commercial register change
November 25, 2025
Employees
11 to 20
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    BA
    BioVersys AG
    Basel
    RP
    Rhizen Pharmaceuticals AG
    Basel
    TA
    Torqur AG
    Basel
    RS
    Regeneron Switzerland GmbH
    Basel
    SB
    SOTIO Biotech AG
    Basel
    NA
    Novaremed AG
    Basel
    FT
    FoRx Therapeutics AG
    Basel
    LB
    Luzsana Biotechnology Europe AG
    Basel